COVID-19 and Gilead

Selected Headlines

Date Headline (link) Source Relevant Snippet
4/3/2021 ... GILEADA new government report says the United States spent $162 million getting Gilead‚Aos covid-19 drug remdesivir to market but opted against seeking government patents because Gilead invented the experimental medicine years earlier.A dose of the drug remdesivir sits on a table in Santa Cruz, Bolivia, on Feb. 18. (Juan Carlos Torrejon/EPA-EFE/Shutterstock)The drug sells for $3,120 for a five-day course of treatment ...
4/1/2021 Gilead has sole rights to COVID-19 blockbuster Veklury, GAO concludes | FiercePharma FiercePharma Throughout the frantic response to the pandemic last year, drugmakers worldwide tested hundreds of potential treatments. Gilead‚Aos antiviral remdesivir quickly rose to the top of treatment guidelines, and with the pandemic spiraling out of ... the drug this year. Right now, about half of hospitalized COVID-19 patients are treated with the drug, Gilead said ...
3/31/2021 Emergency Use Authorizations for COVID-19 Drugs Sought by Humanigen, NeuroDx Emergency Use Authorizations for COVID-19 Drugs Sought by Humanigen, NeuroRx March 31, 2021 241 ShareTwo COVID-19 drug developers said they will seek emergency use authorizations (EUAs) from the FDA for their therapeutics following positive late-stage clinical results.Humanigen disclosed topline Phase III results showing that hospitalized patients who received lenzilumab and other treatments‚Aiincluding steroids and/or Gilead Sciences‚Ao marketed drug Veklury (remdesivir)‚Aihad a ...
3/29/2021 Humanigen's COVID-19 phase 3 hits goal, sending stock soaring | FierceBiotech FierceBiotech A phase 3 clinical trial of Humanigen‚Aos lenzilumab in hospitalized COVID-19 patients has met its primary endpoint. Humanigen plans to use the data to seek emergency use authorization from the FDA.Lenzilumab targets ... top of standard-of-care treatments such as dexamethasone and Gilead Sciences' Veklury.After 28 days, the rate of ventilator-free survival was higher in the lenzilumab arm, causing the trial to hit its primary ...
3/29/2021 Matinas BioPharma Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights ... Gilead‚Aos antiviral COVID-19 medication remdesivir has progressed into in vitro studies ‚Ai ‚Ai Data from ENHANCE-IT study of LYPDISO‚N¢ against Vascepa¬Æ support continued development of LYPDISO as a potential best-in-class prescription-only omega-3 with robust EPA-levels; partnership process ongoing ‚Ai ‚Ai Management to host conference call today, Monday, March 29th, at 8:00 a.m. ET ‚Ai BEDMINSTER, N.J., March 29, 2021 (GLOBE ...
3/22/2021 RedHill Biopharma Announces Compassionate Use Treatment with Opaganib of first COVID-19 Patients in Switzerland ... COVID-19 pneumonia.Acting rapidly to ensure emergency transport and supply of drug, treatment was initiated with orally-administered opaganib within the past week. Opaganib is a novel, orally-administered sphingosine kinase-2 (SK2) inhibitor with demonstrated dual anti-inflammatory and antiviral activity, targeting a human cell component involved in viral replication and therefore expected to be effective against emerging viral variants with mutations in the spike protein.Gilead Raday ...
3/19/2021 Google Alert - Job Home ... The experience has been ... Flag as irrelevant ER nurse talks moving back home after taking measures to protect family from COVID-19 NEWS10 ABC He tried to avoid bringing the virus home from his job ... work at home ... Flag as irrelevant Amid back office consolidation, Gilead axes 179 jobs in California Endpoints News Senior Editor. Gilead is chopping 179 jobs in its home state of California as it scales down ...
3/12/2021 phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia ... COVID-19 pneumonia receiving standard of care. No new safety signals were identified for Actemra/RoActemra in the REMDACTA trial. The study was conducted in collaboration with Gilead Sciences, Inc.Roche will continue to evaluate data from the REMDACTA, COVACTA and EMPACTA studies as well as other studies of Actemra/RoActemra in COVID-19 pneumonia. The EMPACTA study met its primary endpoint, while COVACTA did not meet its primary endpoint ...
3/11/2021 Roche's Actemra drug continues mixed COVID-19 run after failing trial with Gilead's remdesivir Yahoo News By John MillerZURICH (Reuters) - Swiss drugmaker Roche said on Thursday adding its drug Actemra to Gilead Sciences' Veklury medication, also called remdesivir, did not reduce hospital stays for patients with severe COVID-19 pneumonia.Roche's anti-inflammatory Actemra combined with Veklury, Gilead's antiviral drug, failed to reduce hospitalisation durations in the REMDACTA trial, which compared the cocktail with treatment using only Veklury and standard care, Roche said.The trial ...
3/11/2021 Genentech, a member of the Roche Group (SIX: RO, R ... COVID-19 pneumonia receiving standard of care. No new safety signals were identified for Actemra in the REMDACTA trial. The study was conducted in collaboration with Gilead Sciences, Inc.Genentech will continue to evaluate data from the REMDACTA, COVACTA and EMPACTA studies as well as other studies of Actemra in COVID-19 pneumonia. The EMPACTA study met its primary endpoint, while COVACTA did not meet its primary endpoint. Both were ...
3/11/2021 ... COVID-19 pneumonia receiving standard of care. No new safety signals were identified for Actemra in the REMDACTA trial. The study was conducted in collaboration with Gilead Sciences, Inc.Genentech will continue to evaluate data from the REMDACTA, COVACTA and EMPACTA studies as well as other studies of Actemra in COVID-19 pneumonia. The EMPACTA study met its primary endpoint, while COVACTA did not meet its primary endpoint. Both were ...
3/11/2021 Genentech Provides Update on the Phase III REMDACTA Trial of Actemra Plus Veklury in Patients With Severe COVID-19 Pneumonia ... COVID-19 pneumonia receiving standard of care. No new safety signals were identified for Actemra in the REMDACTA trial. The study was conducted in collaboration with Gilead Sciences, Inc.Genentech will continue to evaluate data from the REMDACTA, COVACTA and EMPACTA studies as well as other studies of Actemra in COVID-19 pneumonia. The EMPACTA study met its primary endpoint, while COVACTA did not meet its primary endpoint. Both were ...
3/11/2021 Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia Products Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia The REMDACTA clinical trial of Actemra/RoActemra plus Veklury did not meet its ... the REMDACTA trial. The study was conducted in collaboration with Gilead Sciences, Inc.Roche will continue to evaluate data from the REMDACTA, COVACTA and EMPACTA studies as well as other studies of Actemra/RoActemra in ...
2/15/2021 Europe Cell and Gene Therapy Market Report 2021-2026: Prominent Players are Novartis, Spark Therapeutics, Amgen, Gilead Sciences & Organogenesis Yahoo News ... Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Europe Cell and Gene Therapy Market ReportThe Europe cell ... the market growth.INSIGHTS BY VENDORSNovartis, Spark Therapeutics, Amgen, Gilead Sciences, and Organogenesis are the leading players in the Europe cell and gene therapy market. The market offers tremendous growth opportunities for existing and ...
2/12/2021 As Covid Evolves, Treatments May Prove as Important as Vaccines - WSJ The Wall Street Journal New Covid-19 variants are eluding antibody treatments and may render vaccines less effective. To keep up, physicians need a broader arsenal of therapies that the virus can‚Aot easily defeat. But the Food and Drug Administration has authorized precious few treatments for Covid-19, namely Gilead‚Aos antiviral remdesivir and monoclonal antibodies by Regeneron Pharmaceuticals and Eli Lilly . The National Institutes of Health has prioritized monoclonal antibodies ‚Aiessentially manufactured ...
2/12/2021 As Covid Evolves, Treatments May Prove as Important as Vaccines The FDA has approved only a few therapeutic drugs. Many studies suggest promising options. ... Covid-19 variants are eluding antibody treatments and may render vaccines less effective. To keep up, physicians need a broader arsenal of therapies that the virus can‚Aot easily defeat. But the Food and Drug Administration has authorized precious few treatments for Covid-19, namely Gilead‚Aos antiviral remdesivir and monoclonal antibodies by Regeneron Pharmaceuticals and Eli Lilly . The National Institutes of Health has prioritized monoclonal antibodies ‚Aiessentially manufactured copies ...
2/12/2021 Listen: The state of the pandemic & the hunt for Covid-19 drugs – STAT Posted by Editor - Finance Top Stories Feb 12, 2021 COVID-19 0
When will we have enough vaccine doses? How many effective Covid-19 drugs are just waiting to be found? And what do Redditors ... Covid-19. Lastly, we embark on a lightning round, covering Gilead Sciences‚Ao latest setback, a schism in Alzheimer‚Aos disease research, and a preview of the newest podcast from STAT.For more on what ...
2/10/2021 Recon: FDA issues EUA for Lilly antibody combo; Federal court tosses 'skinny labeling' decision - Regulatory Focus ... Gilead‚Aos Galapagos deal falls apart, a black mark for CEO O‚AoDay ( STAT ) ( Endpoints ) ( Reuters ) Eli Lilly's antibody combination receives FDA EUA for COVID-19 ( Reuters ) ( Endpoints ) ( FDA ) FDA panel admonishes Merck with a gentle ‚Ai and rare ‚Ai slapdown for rushing its pitch on an accelerated OK for adjuvant Keytruda in TNBC ( Endpoints ) ( Pink Sheet ) To the delight of generic drug makers, federal appeals court tosses controversial ‚Aoskinny ...
2/10/2021 A look at promising and overhyped COVID therapies after a tumultuous year of research ... 9, 2021 3:31 PM By: Canadian Press Share via Text MessageTORONTO ‚Ai Alongside the headline-grabbing race for a COVID-19 vaccine, the hunt for effective treatments has unfolded with its own share of ... CANADA-APPROVEDRemdesivir ‚Ai Sold under the name Veklury, this Gilead Sciences drug was among various treatments given to former U.S. President Donald Trump when he successfully overcame COVID-19 last year. But its ability ...
2/10/2021 A look at promising and overhyped COVID therapies after a tumultuous year of research ... overhyped COVID therapies after a tumultuous year of research By PrintTORONTO ‚Ai Alongside the headline-grabbing race for a COVID-19 vaccine, the hunt for effective treatments has unfolded with its own share of ... CANADA-APPROVEDRemdesivir ‚Ai Sold under the name Veklury, this Gilead Sciences drug was among various treatments given to former U.S. President Donald Trump when he successfully overcame COVID-19 last year. But its ability ...
2/5/2021 Gilead stock rallies as it reports $1.9 billion in sales for its COVID-19 drug in Q4 Bitcoin Ethereum NewsShares of Gilead Sciences Inc.‚Aos stock gained 2.1% in after-hours trading on Thursday after the drug maker surprised investors with better-than-expected sales of its COVID-19 drug Veklury during the fourth quarter of 2020.The antiviral COVID-19 treatment, which was called remdesivir until it received a full approval from the Food and Drug Administration in October, generated $1.9 billion in sales in ...
2/4/2021 Gilead stock rallies as it reports $1.9 billion in sales for its COVID-19 drug in Q4 - MarketWatch MarketWatch Shares of Gilead Sciences Inc.‚Aos stock gained 2.1% in after-hours trading on Thursday after the drug maker surprised investors with better-than-expected sales of its COVID-19 drug Veklury during the fourth quarter of 2020.The antiviral COVID-19 treatment, which was called remdesivir until it received a full approval from the Food and Drug Administration in October, generated $1.9 billion in sales in the fourth quarter ...
2/3/2021 Global Liposomal Drug Delivery Devices Market 2020: Major Players are Fudan-Zhangjiang, Pacira, Johnson and Johnson, Gilead Sciences, Novartis, Luye Pharma, CSPC, Ipsen and Teva Pharma ‚Äì ResearchAndMarkets.com | Financial Buzz ... COVID-19 Growth and Change‚Au report has been added to ResearchAndMarkets.com‚Aos offering.Liposomal Drug Delivery Devices Global Market Report 2020-30: COVID 19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global liposomal drug delivery devices market.Major players in the liposomal drug delivery devices market are Fudan-Zhangjiang, Pacira, Johnson and Johnson, Gilead Sciences, Novartis, Luye Pharma ...
1/29/2021 Hospital distributes vaccines for next phase - Morrow County Sentinel MOUNT GILEAD ‚Ai Retired Mount Gilead High School Librarian Ilene Stambaugh was pleased to get her first vaccine injection Thursday at Morrow County Hospital.‚AuI hardly felt it,‚Au said Stambaugh. ‚AuIt didn‚Aot hurt ... that they would be receiving 200 doses of Pfizer-Biontech Covid-19 vaccine for Phase 1B for adults 75 and older.Hospital staff immediately began calling from their lists of patients and word also got ...
1/28/2021 Remdesivir, Given to Half of Hospitalized Covid Patients in U.S., Is Big Win for Gilead ‚Äî Boosted by Taxpayers Physicians Weekly Remdesivir, Given to Half of Hospitalized Covid Patients in U.S., Is Big Win for Gilead ‚Ai Boosted by TaxpayersJan 27, 2021This story also ran on San Francisco Chronicle . It can be republished for free.It was the end of April ‚Ai just as the U.S. confirmed its millionth covid-19 case and 50,000 deaths ‚Ai when White House adviser Dr. Anthony Fauci announced ‚Auhighly significant‚Au news about ...